Revolution Medicines is dedicated to discovering, developing, and delivering innovative targeted medicines for cancer patients. The company focuses on RAS-addicted cancers, which represent 30 percent of new human cancer diagnoses. Revolutionaries work tirelessly to develop cutting-edge therapeutic approaches, setting them apart in the industry with their commitment to tackling some of the toughest cancers.
Revolution Medicines is a clinical-stage precision oncology company focused on inhibiting RAS-addicted cancers. The Senior Scientist I role focuses on using immuno-oncology expertise to advance assets in preclinical and clinical development, particularly within the Cancer Immunology team. This position involves designing and executing studies, identifying novel biomarkers, and contributing to both internal and external scientific publications.
Revolution Medicines is dedicated to discovering, developing, and delivering innovative targeted medicines for cancer patients. The company focuses on RAS-addicted cancers, which represent 30 percent of new human cancer diagnoses. Revolutionaries work tirelessly to develop cutting-edge therapeutic approaches, setting them apart in the industry with their commitment to tackling some of the toughest cancers.
Biocytogen